Clinical Trials Sponsored by Verona Pharma plc

Total 385 results

Verona Pharma Inc

Completed

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

Coronavirus Infection | Covid-19 | SARS-CoV-2

United States
Verona Pharma plc

Completed

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

COPD

United States, United Kingdom
Verona Pharma plc

Completed

SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

Chronic Obstructive Pulmonary Disorder | Inflammatory Disorder of the Respiratory Tract

United Kingdom
Verona Pharma plc

Completed

Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients

COPD

United Kingdom, Poland, Germany, Bulgaria, Czechia, Romania
Verona Pharma plc

Completed

The Effects of RPL554 in Addition to Tiotropium in COPD Patients

Chronic Obstructive Pulmonary Disease Moderate
Verona Pharma plc

Completed

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

Asthma

Sweden, United Kingdom
Verona Pharma plc

Completed

The Effects of RPL554 on Top of Standard COPD Reliever Medications

Chronic Obstructive Pulmonary Disease

United Kingdom
Verona Pharma plc
Cystic Fibrosis Trust

Completed

A Study of RPL554 in Patients With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Verona Pharma plc
Iqvia Pty Ltd

Completed

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Chronic Obstructive Pulmonary Disease

Korea, Republic of, United States, Bulgaria, Czechia, Germany, Greece, Hungary, Poland, Romania, Russian Federation, Slovakia, United Kingdom
Verona Pharma plc
Iqvia Pty Ltd

Completed

A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease

COPD

United Kingdom
Verona Pharma plc
Iqvia Pty Ltd

Completed

Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler

Pulmonary Disease, Chronic Obstructive

United States
Verona Pharma plc
Iqvia Pty Ltd

Completed

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Chronic Obstructive Pulmonary Disease

Denmark, United States, Bulgaria, Belgium, Poland, Spain, Canada, Estonia, Hungary, Slovakia
Verona Pharma plc
University of Alabama at Birmingham

Recruiting

Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

COPD

United States
Verona Pharma plc
Iqvia Pty Ltd; LGC Limited

Completed

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

COPD

United States
University of Parma
Universita di Verona

Completed

Healthy Effects of an Innovative Probiotic Pasta (SFLABPASTA)

OBESITY | INFLAMMATION | DYSLIPIDEMIA | CONSTIPATION

Italy
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
Yuria-Pharm
Pharmaxi LLC

Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Covid19

Ukraine
4D pharma plc

Terminated

A Study of MRx-4DP0004 in Asthma

Asthma

United States, United Kingdom
Herantis Pharma Plc.

Active, not recruiting

Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE) (AdeLE)

Secondary Lymphedema

Finland, Sweden
4D pharma plc

Terminated

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Herantis Pharma Plc.

Terminated

A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema

Secondary Lymphedema

Finland
Poolbeg Pharma plc

Completed

Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses

Influenza, Human

Netherlands
Destiny Pharma Plc

Completed

Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects

Staphylococcus Aureus Infection

United Kingdom
Destiny Pharma Plc

Completed

Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

Staphylococcal Infections | Surgical Site Infection

United States, Serbia, Georgia
4D pharma plc

Completed

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States, United Kingdom, Ireland
Destiny Pharma Plc

Completed

Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)

Staphylococcal Infection

United Kingdom
Redx Pharma Plc

Completed

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Colorectal Cancer

Spain, Korea, Republic of, United Kingdom, United States
Redx Pharma Plc

Active, not recruiting

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Cancer | Solid Tumor

United Kingdom
4D pharma plc

Withdrawn

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma (AVENU)

Urothelial Carcinoma

United States
4D pharma plc

Withdrawn

A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19

COVID-19

United Kingdom
4D pharma plc

Completed

Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease

Crohn's Disease

United Kingdom
Herantis Pharma Plc.
Renishaw plc.

Completed

Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study

Brain Diseases | Nervous System Diseases | Parkinson Disease | Movement Disorders | Neuro-Degenerative Disease

Sweden, Finland
Herantis Pharma Plc.
Renishaw plc.

Completed

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease

Brain Diseases | Nervous System Diseases | Parkinson Disease | Movement Disorders | Neurodegenerative Diseases

Sweden, Finland
Redx Pharma Plc
Merck Sharp & Dohme LLC

Completed

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86)

Advanced Solid Tumours

United Kingdom, Australia
4D pharma plc
Merck Sharp & Dohme LLC

Terminated

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Oncology

United States
Renishaw
Herantis Pharma Plc.

Active, not recruiting

Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions

Brain Diseases | Nervous System Diseases | Parkinson Disease | Movement Disorders | Neuro-Degenerative Disease

Finland, Sweden
LEO Pharma
ICON plc

Completed

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

Healthy Volunteers

Netherlands
PLx Pharma

Completed

Pharmacodynamic and Pharmacokinetic Study of PL-ASA

Healthy Volunteers

United States
PLx Pharma

Completed

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients (RITE)

Diabetes Mellitus, Type 2

United States
PLx Pharma

Completed

Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

Gastroduodenal Ulceration

United States
PLx Pharma

Completed

Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

Bioequivalence

United States
PLx Pharma

Completed

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

Diabetes Mellitus, Type 2

United States
PLx Pharma

Completed

Food-Effect Pharmacokinetic Study of PL2200

Healthy

United States
PLx Pharma

Completed

Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

Bioequivalence
PLx Pharma

Completed

Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers

Upper Gastrointestinal Mucosal Damage

United States
Redx Pharma Plc
Simbec Research

Completed

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Liver Diseases | Fibrosis | Kidney Diseases | Inflammation | Idiopathic Pulmonary Fibrosis | Non-alcoholic Steatohepatitis

United Kingdom
Herantis Pharma Plc.
ORA, Inc.

Completed

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Dry Eye Syndrome

United States
Redx Pharma Plc
Simbec Research

Recruiting

Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Fibrosis | IPF

Italy, Spain, United States, Belgium, United Kingdom, Austria, Czechia, Poland, Switzerland
Simone Lumetti
Geistlich Pharma AG; Dentsply Sirona Implants and Consumables

Unknown

Impact of a Alveolar Ridge Preservation Technique on the Need of Performing Guided Bone Regeneration for Dental Implant Placement

Tooth Avulsion

Italy
Fulgent Pharma LLC.

Recruiting

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

United States

3

Subscribe